Vision Shopsters: Biotech Success Rates 2003-2009

The biotech industry is the driver of innovation in new treatment

. Nevertheless, there is no clear data on the success rates of Biotech companies in drug development.

This report summarized the success rates of 211 publicly traded biotech companies with more than 1,500 drugs in development fort he period 2002 - 2009. The success rates are discussed per disease group and put into context to existing data on drug development attrition rates. The report also gives on outlook on the resulting implications for stakeholders of the biotech industry based on the identified drawbacks in the current biotech business model.

For more, kindly visit : http://www.visionshopsters.com/product/3363/Biotech-Success-Rates-2003-2009.html

Table Of Contents :

1 Introduction

1.1 Why a study on success rates of biotech companies?

1.2 What are success rates?

1.3 The role of success rates

1.4 Are success rates of biotech companies different?

2 Methods

2.1 Origin of Data

2.2 Difference between FDA and EMEA

2.3 Time frame

2.4 Success rates per molecule vs. success rates per indication

2.5 Companies of the sample

3 Results

3.1 Reporting of success and failure

3.2 Distribution of sample over disease groups

3.3 Overall biotech success rates (IND to approval)

3.4 Disease group specific overall success rates (IND to approval)

3.5 Number of projects in different disease groups

3.6 Disease group specific Success Rates

3.6.1 Cancer (471 projects)

3.6.2 Neurology (157 projects)

3.6.3 Infectious (56 projects)

3.6.4 Inflammation (127 projects)

3.6.5 Cardiovascular (85 projects)

3.6.6 Pain management (75 projects)

3.6.7 Dermatology (31 projects)

3.6.8 Endocrinology (27 projects)

3.6.9 Metabolic (66 projects)

3.6.10 Genitourinary (38 projects)

3.6.11 Hematology (28 projects)

3.6.12 Gastrointestinal (28 projects)

4 Discussion

4.1 Success Rates in Biotech (Avance) and Pharma (Kola, Landis)

4.2 Difference in cancer

4.3 Difference in Neurology

4.4 Difference in Infectious Diseases

4.5 Difference in Inflammation

4.6 Difference in Cardiovascula

4.7 Biotech has more late stage failures

4.8 Case Study: Arpida

4.9 Biotech does not abandon low potential drugs

5 Conclusion

For more information on the report, kindly visit :

http://www.visionshopsters.com/product/3363/Biotech-Success-Rates-2003-2009.html

or email us your query at : info@visionshopsters.com or visit : www.visionshopsters.com

----------------------------------------------

by: Vision Shopsters

POST COMMENT

Seattle Mariners Tickets - Mariners In Good Shape To Challenge For Division Vision Shopsters: Us Smart Grid Roll-out: Forging Ahead DePuy Hip Implant Revisions Chip Away at Recipient Confidence Laser Vision Correction Basics How Much Will I Pay for Vision Care? 2010 Worldwide Battery Manufacturing Industry Report added in Vision Shopsters Being Structurally Sound: Revision Rhinoplasty Procedures 2010 Worldwide Bed & Breakfast Inns Industry Report added in Vision Shopsters 2010 Worldwide CD, Record & Tape Recording Industry Report added in Vision Shopsters Duke Peterson Vision Without Glasses Features Of Sumvision Cyclone 2010 Worldwide Commodity Contracts Dealing Industry Report added in Vision Shopsters Visualase: Where you can get the best laser vision correction